<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04591197</url>
  </required_header>
  <id_info>
    <org_study_id>HS-NF-2020</org_study_id>
    <nct_id>NCT04591197</nct_id>
  </id_info>
  <brief_title>Flumatinib Efficacy and Safety for New Diagnosed Chronic Phase Chronic Myeloid Leukemia</brief_title>
  <official_title>Flumatinib Efficacy and Safety for New Diagnosed Chronic Phase Chronic Myeloid Leukemia : A Prospective, Multi-center, Single Arm Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall survival (OS)of Chronic myeloid leukemia (CML) has been significantly improved&#xD;
      since the advent of Tyrosine kinase inhibitors (TKIs) .Nevertheless, there still exists a&#xD;
      amount of patients who has poor response or intolerance for TKI drugs( Imatinib, dasatinib,&#xD;
      nilotinib). Flumatinib has been shown to be a more potent inhibitor of BCR-ABL1 tyrosine&#xD;
      kinase than imatinib,and it aslo has better security when compared to other TKIs(Imatinib,&#xD;
      dasatinib, nilotinib).It will be a better chioce for CML patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MMR rates at 12 months</measure>
    <time_frame>12 monts</time_frame>
    <description>MMR(BCR/ABL(IS)&lt;0.1%) at 12 months after treating</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VEMR rates at 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>VEMR((BCR-ABL1/ABL1≤ 40% on the International Scale) at 4weeks after treating</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Validity and Safety</condition>
  <eligibility>
    <study_pop>
      <textblock>
        New diagnosed CML-CP patients who are more than 18 years old.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years old, both male and female;&#xD;
&#xD;
          2. New Diagnosed Chronic Phase Chronic Myeloid Leukemia.&#xD;
&#xD;
          3. Within half a year after diagnosis of CML;&#xD;
&#xD;
          4. Previous TKIs treatment was less than 2 weeks;&#xD;
&#xD;
          5. The pregnant test of female patients was negative (within 7 days before medication&#xD;
             before enrollment);&#xD;
&#xD;
          6. Informed consent of the patient or his legal representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. T315I mutation is known to exist;&#xD;
&#xD;
          2. Rare atypical transcript types that cannot be standardized internationally;&#xD;
&#xD;
          3. Received TKI drugs for more than 2 weeks before enrollment;&#xD;
&#xD;
          4. Received interferon therapy for more than 3 months before enrollment;&#xD;
&#xD;
          5. Received other anti-CML drugs (except hydroxyurea) for more than 2 weeks or surgical&#xD;
             treatment (including hematopoietic stem cell transplantation)&#xD;
&#xD;
          6. patients who participate in other clinical studies at the same time;&#xD;
&#xD;
          7. patients who having had major surgery or not recovered from surgery within 4 weeks;&#xD;
&#xD;
          8. patients who having history of malignant tumor&#xD;
&#xD;
          9. Woman who is pregnant or nursing&#xD;
&#xD;
         10. Eastern Cooperative Oncology Group Physical Performance Status Score (ECOG PS) &gt; 3;&#xD;
&#xD;
         11. Patients known to be allergic or contraindicated to the study drug (APIs and/or&#xD;
             excipients).&#xD;
&#xD;
         12. A clear history of neurological or psychiatric disorders, including epilepsy or&#xD;
             dementia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Na Xu, doctor</last_name>
    <phone>18620698390</phone>
    <email>sprenaa@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>NanfangH</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xu na, doctor</last_name>
      <phone>18620698390</phone>
      <email>sprenaa@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>xuna</investigator_full_name>
    <investigator_title>Associate chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

